Last reviewed · How we verify

NCT07137091

Motion for Recovery: The Impact of Gyrokinesis on Childhood Cancer-Related Fatigue.

Completed NA Last updated 3 March 2026
What this trial tests

NA trial testing Gyrokinesis exercise in Fatigue in 80 participants. Completed in 5 February 2026.

Timeline
1 October 2025
Primary endpoint
1 February 2026
5 February 2026

Quick facts

Lead sponsorMTI University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment80
Start date1 October 2025
Primary completion1 February 2026
Estimated completion5 February 2026
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

MTI University

Who can join

Adults 12 to 18, any sex, with Fatigue. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CRF influences engagement in everyday activities, mood, sleep, social relations, school attendance, academic achievement, and quality of life . It was significantly associated with low health-related quality of life in pediatric cancer patients including leukemia . Since attention to managing cRF has been drawn, only a few non-pharmacological strategies were tested for their effectiveness in reducing cRF among children. Physical activity (Pa) has been proven to be the most effective strategy . Yet adherence to Pa remains problematic.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Fatigue

Currently open trials in the same condition.

Other MTI University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07137091.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing